Efficacy of Lornoxicam (Xefocam) in the Treatment of Gonarthritis in Patients with Osteoarthritis

I.Yu. Golovach, I.P. Semeniv, T.M. Chipko, Ye.A. Lazorenko


38 patients with gonarthritis, complicated with relapsing synovitis, underwent a course of treatment with lornoxicam. The purpose of the study was to assess the efficacy and safety of lornoxicam. As a result of lornoxicam use, we noted quickly and reliably positive dynamics of pain and inflammatory syndromes, which is confirmed by the change of pain index, knee circumference and ultrasound examination data. Results of parenteral administration of lornoxicam confirm its high efficacy in the rapid relief of synovitis symptoms and in reducing pain syndrome. Thus, lornoxicam is effective and safe nonsteroidal anti-inflammatory drug and can be recommended for widespread use in the treatment of recurrent synovitis in patients with gonarthritis.


osteoarthritis; synovitis; lornoxicam; efficcacy


Головач І.Ю. Ефективність і безпечність лорноксикаму (ксефокаму) в лікуванні ревматичних захворювань суглобів // Травма. — 2013. — № 2(14). — С. 90-94.

Коваленко В.Н., Борткевич О.П. Остеоартроз і біль: стан проблеми // Боль. Суставы. Позвоночник. — 2011. — № 1. — С. 10-14.

Олюнин Ю.А. Хронический синовит в ревматологии. Оценка активности и тактика лечения // Русский медицинский журнал. — 2005. — Т. 13, № 8. — С. 548-555.

Хитров Н.А. Полиморфизм болевого синдрома при остеоартрозе, обезболивающая и противовоспалительная терапия // Трудный пациент. — 2011. — Т. 9, № 4. — С. 49-53.

Цурко В.В., Балабанова Р.М., Олюнин Ю.А. и др. Внутрисуставное введение лорноксикама: клинико-экспериментальное обоснование и оценка эффективности // Consilium Medicum. — 2006. — Т. 8, № 7. — С. 56-59.

Altman R., Asch E., Bloch D. еt al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis // Arthr. Rheum. — 1991. — № 34. — P. 505-514.

Berg J., Fellier H., Christoph T., Grarup J., Stimmeder D. Theanalgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, in ducible nitric oxide synthase (iNOS), and the for mation of interleukin (IL)-6 in vitro // Inflamm. Res. — 1999. — Vol. 48(7). — P. 369-379.

Berry H., Bird H., Black C. еt al. A double-blind, mullicentre, placebocontrolled trial of lornoxicam in patients with osteoarthritis of the hip and knee // Ann. Rheum. Dis. — 1992. — Vol. 51. — P. 238-242.

Capone M.L., Tacconelli S., Patrignani P. еt al. Pharmacodynamic of cyclooxygenase inhibitors in humans // Prostagland. Other Lipid Mediat. — 2007. — Vol. 82. — P. 85-94.

Rainer F., Klein G., Mayrhofer F., Singer F., Uray H., Kursten F.W. A prospective, multicentre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain // Eur. J. Clin. Res. — 1996. — Vol. 8. — P. 1-13.

Sellam J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis // Nat. Rev. Rheumatol. — 2010. — Vol. 6(11). — P. 625-635.

Sokolove J., Lepus Ch.M. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations // Ther. Adv. Musculoskel. Dis. — 2013. — Vol. 5(2). — P. 77-94.

Wenham C.Y.J., Conaghan Ph.G. The Role of Synovitis in Osteoarthritis // Ther. Adv. Musculoskelet. Dis. — 2010. — Vol. 2(6). — P. 349-359.

Copyright (c) 2016 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта